The Angiotensin Receptor Neprilysin Inhibitor LCZ696 is Effective Across the Spectrum of Ejection Fraction in Heart Failure With Reduced Ejection Fraction

The angiotensin receptor neprilysin inhibitor LCZ696 reduced cardiovascular morbidity and mortality compared to enalapril in the PARADIGM-HF Trial. We evaluated the influence of ejection fraction on clinical outcomes and on the effectiveness of LCZ696 compared with enalapril.

Source: Journal of Cardiac Failure - July 31, 2015 Category: Cardiology Authors: Scott Solomon, Milton Packer, Michael Zile, Karl Swedberg, Jean Rouleau, Martin Lefkowitz, Victor Shi, Akshay Desai, Brian Claggett, Randall Starling, John J.V. McMurray Tags: Clinical Trials I Source Type: research